RIGL

Rigel Pharmaceuticals, Inc. [RIGL] Stock Forecast

Q: What is Rigel Pharmaceuticals, Inc. stock symbol ?

Rigel Pharmaceuticals, Inc. is a US stock, located in South san francisco of Ca and trading under the symbol RIGL

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

RIGL Stock Summary

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

Earnings are expected to fall -100% next year

Profit margins (-0.22%) are lower than the previous year (-0.21%)

RIGL has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

RIGL

Top 10 Correlated Stocks

RIGL

In the News

RIGL Financial details

Company Rating

Neutral

Market Cap

210.45M

Income

-25.9M

Revenue

116.88M

Book val./share

-0.16

Cash/share

0.33

Dividend

Dividend %

Employees

147

Optionable

Shortable

Yes

Earnings

30 Apr 2024

P/E

-8.08

Forward P/E

PEG

1.38

P/S

1.8

P/B

-7.31

P/C

3.18

P/FCF

-10.08

Quick Ratio

1.64

Current Ratio

1.86

Debt / Equity

-2.11

LT Debt / Equity

-1.84

EPS (TTM)

-0.15

EPS next Y

EPS next Q

EPS this Y

-61.11%

EPS next Y

EPS next 5Y

EPS last 5Y

-18.94%

Revenue last 5Y

14.54%

Revenue Q/Q

27.22%

EPS Q/Q

-112.88%

SMA20

SMA50

SMA100

Inst Own

54.34%

Inst Trans

0.86%

ROA

-22%

ROE

92%

ROC

-0.32%

Gross Margin

94%

Oper. Margin

-18%

Profit Margin

-22%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.71-1.96

52W High

52W Low

RSI

Rel Volume

0.49

Avg Volume

1.28M

Volume

626.31K

Perf Week

-14.63%

Perf Month

-33.12%

Perf Quarter

43.8%

Perf Half Y

9.88%

Beta

0.977

Volatility

0.06%, 0.14%

Prev Close

Price

1.05

Change

-6.25%

RIGL Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.35	0.64	0.88	0.7	0.67
Net income per share	-0.4	-0.18	-0.11	-0.36	-0.14
Operating cash flow per share	-0.25	-0.31	0.03	-0.43	-0.03
Free cash flow per share	-0.26	-0.32	0.03	-0.43	-0.12
Cash per share	0.59	0.34	0.73	0.34	0.33
Book value per share	0.32	0.2	0.18	-0.08	-0.16
Tangible book value per share	0.32	0.2	0.18	-0.17	-0.24
Share holders equity per share	0.32	0.2	0.18	-0.08	-0.16
Interest debt per share	0.22	0.24	0.21	0.26	0.39
Market cap	358.24M	590.64M	451.8M	258.61M	252.32M
Enterprise value	372.03M	599.35M	463.48M	275.7M	280.12M
P/E ratio	-5.38	-19.43	-25.22	-4.2	-10.06
Price to sales ratio	6.04	5.44	3.03	2.15	2.16
POCF ratio	-8.63	-11.32	76.86	-3.51	-43.94
PFCF ratio	-8.34	-11.05	86.04	-3.48	-12.16
P/B Ratio	6.66	17.36	14.87	-18.99	-8.81
PTB ratio	6.66	17.36	14.87	-18.99	-8.81
EV to sales	6.27	5.52	3.11	2.29	2.4
Enterprise value over EBITDA	-5.59	-21.11	-51.91	-5.15	-16.5
EV to operating cash flow	-8.96	-11.49	78.85	-3.74	-48.78
EV to free cash flow	-8.66	-11.21	88.26	-3.72	-13.5
Earnings yield	-0.19	-0.05	-0.04	-0.24	-0.1
Free cash flow yield	-0.12	-0.09	0.01	-0.29	-0.08
Debt to equity	0.67	1.15	1.01	-3.05	-2.11
Debt to assets	0.25	0.35	0.18	0.31	0.52
Net debt to EBITDA	-0.21	-0.31	-1.31	-0.32	-1.64
Current ratio	2.04	2.18	2.43	1.78	1.86
Interest coverage	-206.24	-21.41	-1.85	-14.63	-2.98
Income quality	0.62	1.75	-0.33	1.26	0.23
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.89	0.55	0.44	0.5	0.21
Intangibles to total assets	0	0	0	0.11	0.12
Capex to operating cash flow	0.04	0.02	-0.11	0.01	2.61
Capex to revenue	-0.02	-0.01	0	0	-0.13
Capex to depreciation	-2.13	-1.79	-0.54	-0.45	-12.12
Stock based compensation to revenue	0.15	0.07	0.06	0.1	0.08
Graham number	1.7	0.9	0.65	0.8	0.73
ROIC	-0.59	-0.32	-0.13	-1.9	-0.68
Return on tangible assets	-0.45	-0.28	-0.11	-0.52	-0.24
Graham Net	0.08	-0.04	0.02	-0.32	-0.36
Working capital	60.79M	48.14M	90.91M	50.69M	46M
Tangible asset value	53.82M	34.03M	30.37M	-28.57M	-42.52M
Net current asset value	25.25M	12.63M	17.51M	-31.99M	-46.6M
Invested capital	0.67	1.15	1.01	-3.05	-2.11
Average receivables	7.09M	13.04M	15.72M	27.9M	35.44M
Average payables	5.27M	3.93M	3.75M	13.15M	14.83M
Average inventory	1.12M	1.5M	4.13M	7.87M	7.32M
Days sales outstanding	62.25	53.67	37.84	122.39	95.4
Days payables outstanding	1.67K	1.51K	1.28K	4.7K	366.64
Days of inventory on hand	545.49	668.01	2.23K	1.9K	283.48
Receivables turnover	5.86	6.8	9.65	2.98	3.83
Payables turnover	0.22	0.24	0.29	0.08	1
Inventory turnover	0.67	0.55	0.16	0.19	1.29
ROE	-1.24	-0.89	-0.59	4.52	0.88
Capex per share	-0.01	-0.01	0	0	-0.09

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.3	0.15	0.15	0.16	0.21
Net income per share	0	-0.08	-0.04	-0.03	0
Operating cash flow per share	-0.13	-0.02	0.03	-0.01	-0.04
Free cash flow per share	-0.13	-0.11	0.03	-0.01	-0.04
Cash per share	0.34	0.34	0.37	0.36	0.33
Book value per share	-0.08	-0.14	-0.16	-0.18	-0.16
Tangible book value per share	-0.17	-0.22	-0.24	-0.26	-0.16
Share holders equity per share	-0.08	-0.14	-0.16	-0.18	-0.16
Interest debt per share	0.25	0.36	0.36	0.36	0.36
Market cap	259.28M	229.11M	224.13M	188.31M	252.85M
Enterprise value	276.37M	249.56M	235.99M	203.7M	280.64M
P/E ratio	89.65	-3.99	-8.49	-8.27	85.77
Price to sales ratio	5.06	8.79	8.34	6.69	7.06
POCF ratio	-11.83	-56.24	37.8	-138.57	-40.52
PFCF ratio	-11.79	-12.01	37.8	-136.36	-39.82
P/B Ratio	-19.04	-9.45	-7.97	-5.92	-8.83
PTB ratio	-19.04	-9.45	-7.97	-5.92	-8.83
EV to sales	5.39	9.57	8.78	7.24	7.84
Enterprise value over EBITDA	72.2	-20.84	-49.81	-58.18	95.55
EV to operating cash flow	-12.61	-61.26	39.8	-149.89	-44.97
EV to free cash flow	-12.57	-13.08	39.8	-147.5	-44.19
Earnings yield	0	-0.06	-0.03	-0.03	0
Free cash flow yield	-0.08	-0.08	0.03	-0.01	-0.03
Debt to equity	-3.05	-2.5	-2.16	-1.91	-2.11
Debt to assets	0.31	0.49	0.52	0.53	0.52
Net debt to EBITDA	4.47	-1.71	-2.5	-4.39	9.46
Current ratio	1.78	2.35	2.29	1.97	1.86
Interest coverage	3.2	-10.57	-2.83	-2.35	1.03
Income quality	-15.64	0.3	-0.9	0.24	-8.47
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0.98	0	0
Research and developement to revenue	0.3	0.39	0.18	0.23	0.09
Intangibles to total assets	0.11	0.12	0.12	0.12	0.12
Capex to operating cash flow	0	3.68	0	0.02	0.02
Capex to revenue	0	-0.58	0	0	0
Capex to depreciation	-0.26	-42.02	0	-0.08	-0.38
Stock based compensation to revenue	0.08	0.11	0.08	0.07	0.05
Graham number	0.09	0.51	0.37	0.37	0.12
ROIC	0.06	-0.36	-0.16	-0.17	0
Return on tangible assets	0.01	-0.13	-0.06	-0.06	0.01
Graham Net	-0.32	-0.36	-0.34	-0.37	-0.36
Working capital	50.69M	61.45M	56.9M	46.75M	46M
Tangible asset value	-28.57M	-38.94M	-42.53M	-45.98M	-42.52M
Net current asset value	-31.99M	-40.9M	-44.28M	-52.13M	-46.6M
Invested capital	-3.05	-2.5	-2.16	-1.91	-2.11
Average receivables	27.92M	34.84M	25.09M	22.18M	27.05M
Average payables	12.61M	14.4M	5.77M	6.62M	7.57M
Average inventory	8.12M	10.1M	10.93M	8.45M	5.82M
Days sales outstanding	70.77	101.38	69.69	75.32	76.82
Days payables outstanding	5.92K	579.89	438.7	567.75	169.6
Days of inventory on hand	2.4K	1.02K	902.68	433.82	131.13
Receivables turnover	1.27	0.89	1.29	1.19	1.17
Payables turnover	0.02	0.16	0.21	0.16	0.53
Inventory turnover	0.04	0.09	0.1	0.21	0.69
ROE	-0.05	0.59	0.23	0.18	-0.03
Capex per share	0	-0.09	0	0	0

RIGL Frequently Asked Questions

What is Rigel Pharmaceuticals, Inc. stock symbol ?

Rigel Pharmaceuticals, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol RIGL

What is Rigel Pharmaceuticals, Inc. stock quote today ?

Rigel Pharmaceuticals, Inc. stock price is $1.05 today.

Is Rigel Pharmaceuticals, Inc. stock public?

Yes, Rigel Pharmaceuticals, Inc. is a publicly traded company.

Something similar

Top by Market Cap

BRYN.DE

Company Profile

Volume Average 1.28M
Market Capitalization 210.45M
Employee 147
CEO Mr. Raul R. Rodriguez
Headquarters South San Francisco,CA,US
IPO Date 2000-11-29
Website https://www.rigel.com

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.